 Left ventricular ejection fraction useful end point thrombolytic therapy comparative trials era comparative adjunctive trials reperfusion therapy need alternative end points mortality reduction clear Left ventricular ejection fraction surrogate problematic due values inadequate studies lack correlation mortality results controlled reperfusion trials date paper composite clinical end point order severity adverse outcome death hemorrhagic stroke nonhemorrhagic stroke poor ejection fraction reinfarction heart failure pulmonary edema composite index useful true therapeutic benefit reperfusion trials patient enrollment